Cargando…

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines

Cellular crosstalk between hematopoietic stem/progenitor cells and the bone marrow (BM) niche is vital for the development and maintenance of myeloid malignancies. These compartments can communicate via bidirectional transfer of extracellular vesicles (EVs). EV trafficking in acute myeloid leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang, Jonas B., Buck, Michèle C., Rivière, Jennifer, Stambouli, Oumaima, Sachenbacher, Ken, Choudhary, Purva, Dietz, Hendrik, Giebel, Bernd, Bassermann, Florian, Oostendorp, Robert A. J., Götze, Katharina S., Hecker, Judith S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574064/ https://www.ncbi.nlm.nih.gov/pubmed/36263223 http://dx.doi.org/10.3389/fonc.2022.949261

Ejemplares similares

Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression
por: Weickert, Marie-Theresa, et al.
Publicado: (2021)

Bridging Strategies to Allogeneic Transplant for Older AML Patients
por: Hecker, Judith, et al.
Publicado: (2018)

Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles and Their Potential as Novel Immunomodulatory Therapeutic Agents
por: Börger, Verena, et al.
Publicado: (2017)

Extracellular Vesicles and Chemotherapy Resistance in the AML Microenvironment
por: Nehrbas, Jill, et al.
Publicado: (2020)

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
por: Tabe, Yoko, et al.
Publicado: (2020)

Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells
por: Nian, Zhigang, et al.
Publicado: (2021)

S128: AML CONDITIONING OF THE BONE MARROW MICROENVIRONMENT THROUGH CCR1 LIGAND UP-REGULATION PROMOTES AML STEM CELL PROPAGATION AND IS MIMICKED BY AGEING
por: Ren, Xiying, et al.
Publicado: (2023)

Transmissible ER Stress Reconfigures the AML Bone Marrow Compartment
por: Doron, Ben, et al.
Publicado: (2018)

IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells
por: Liss, Franziska, et al.
Publicado: (2021)

dsDNA from extracellular vesicles (EVs) in adult AML
por: Bernardi, Simona, et al.
Publicado: (2020)

In quest for leukemia initiating cells in AML
por: De Grandis, Maria, et al.
Publicado: (2018)

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment
por: Tabe, Yoko, et al.
Publicado: (2023)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

Choosing the source of healthy controls for studies on myeloid malignancies: all bone marrow cells are created equal, but some are more equal than others
por: Rivière, Jennifer, et al.
Publicado: (2023)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine
por: Jagan, Sucheta, et al.
Publicado: (2012)

Azacitidine-induced reconstitution of the bone marrow T cell repertoire is associated with superior survival in AML patients
por: Grimm, Juliane, et al.
Publicado: (2022)

Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy
por: You, Ruolan, et al.
Publicado: (2021)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade
por: Ruzicka, Michael, et al.
Publicado: (2019)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

The Black Hole: CAR T Cell Therapy in AML
por: Atilla, Erden, et al.
Publicado: (2023)

G-CSF-Associated Bone Marrow Necrosis in AML after Induction Chemotherapy
por: Osuorji, Ikenna, et al.
Publicado: (2012)

P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
por: Dragieva, Y., et al.
Publicado: (2022)

MicroRNA–mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients
por: Bhise, Neha S., et al.
Publicado: (2016)

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
por: Noviello, Maddalena, et al.
Publicado: (2019)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs
por: Li, Hongjiao, et al.
Publicado: (2023)

Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types
por: Green, S R, et al.
Publicado: (2010)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

Targeting glutamine uptake in AML
por: Jacque, Nathalie, et al.
Publicado: (2014)

AML treatment in older adults
por: Sehgal, Alison, et al.
Publicado: (2015)

Impact of CNA on AML prognosis
por: Gonzales, Fanny, et al.
Publicado: (2017)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

Von AML bis Zytokinfreisetzung
por: Klein, Friederike
Publicado: (2022)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_gcl3r3ft3li363e6go7mrovkbu